Real-world and late-phase studies in 'pharmerging' markets: challenges and best practices in implementation

摘要

The focus of biopharma companies is shifting towards "pharmerging" markets as a source of sales growth, with particular attention being paid to the E7 countries - China, India, Brazil, Mexico, Russia, Indonesia and Turkey - whose joint economies are forecast to outstrip those of the G7 countries by 2020. Estimates show that annual global spending on medicines will reach nearly $ 1.2 trillion by 2016 and of that, pharmerging markets will account for 30% of the spending.This will make these combined markets on par with the US as largest contributors to annual global spending. Over the next five years, it is estimated that the pharmerging markets will grow by $ 150-165 billion in spending; this will be driven by lower costs of medicines, increasing incomes and a greater focus by the local governments on improving healthcare, including implementing or supporting programmes to increase access to medicines. One end result will be the increased availability of new medicines in these markets.